LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Other Events
Item 8.01
On September 30, 2019, the Company issued a press release announcing that the first biopsy-confirmed non-alcoholic steatohepatitis (“NASH”) patient was dosed in the LiFT clinical trial with LPCN 1144. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.
| 99.1 | Press Release announcing First Biopsy-Confirmed NASH Patient Dosed in the Lipocine LiFT Study of LPCN 1144 |
Lipocine Inc. Exhibit
EX-99.1 2 tv529812_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FIRST BIOPSY CONFIRMED NASH PATIENT DOSED IN LIPOCINE LIFT STUDY OF LPCN 1144 SALT LAKE CITY,…
To view the full exhibit click here
About LIPOCINE INC. (NASDAQ:LPCN)
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
